Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

KIAA1524

Written2010-01Anchit Khanna, Juha Okkeri, Jukka Westermarck
Centre for Biotechnology, University of Turku, Abo Akademi, Tykistokatu 6A, 20520 Turku, Finland (JO, JW); Institute of Medical Technology, University of Tampere, Biokatu 6-8, 33520 Tampere, Finland (AK)

(Note : for Links provided by Atlas : click)

Identity

Alias_symbol (synonym)CIP2A
Other aliasFLJ12850
MGC163436
p90
HGNC (Hugo) KIAA1524
LocusID (NCBI) 57650
Atlas_Id 44402
Location 3q13.13  [Link to chromosome band 3q13]
Location_base_pair Starts at 108549871 and ends at 108589644 bp from pter ( according to hg19-Feb_2009)  [Mapping KIAA1524.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

 
  Structure of CIP2A gene.
Description The gene spans 38.8 kb and consists of 21 exons.
Transcription 3.3 kb mRNA.
Alternate splicing: there are predicted splice variants, but none of them are experimentally verified.

Protein

 
  Predicted modular structure of CIP2A. The indicated areas represent Armadillo repeats (Arm), leucine zipper (LZ) and coiled coil region. This prediction is based on programs superfamily 1.73 (Arm repeats), Prosite freq pat (leucine zipper) and Smart (coiled coil region). The phosphorylation sites have been identified in Daub et al., (2008) Mol Cell 31, 438-448, and the Ser904 has been reported also in Beausoleil et al., (2006) Nat Biotechnol 24, 1285-1292. Both studies analyzed peptides by mass spectrometry in high-throughput manner.
Description Translation: 905 amino acids.
Family: not defined.
Expression Increased expression of CIP2A/KIAA1524 has been observed in various highly proliferating cancer cells. CIP2A is overexpressed in several types of human cancer tissues (gastric, breast, colon, squamous cell carcinomas of head and neck). Low expression of CIP2A/KIAA1524 is seen in most of the normal tissues, except in testis. CIP2A mRNA and protein expression is positively regulated by oncoprotein MYC whereas no change is seen in CIP2A expression in response to serum stimulation or during the cell cycle. A recent study demonstrated that Helicobacter pylori CagA-induced CIP2A expression is dependent on Src and MEK/ERK pathways.
Localisation Cytoplasmic and perinuclear region.
Function Human oncoprotein. Interacts with Protein Phosphatase 2A (PP2A) and inhibits PP2A-mediated dephosphorylation and subsequent proteolytic degradation of MYC protein. Inhibition of CIP2A expression by siRNA inhibits anchorage-independent growth of several types of human cancer cells. CIP2A inhibition also prevents tumor growth in mouse xenograft models. Two studies have shown that CIP2A siRNA induces expression of acidic b-galactoside indicating induction of cellular senescence.
Homology CIP2A is well-conserved among mammalian species, sharing more than 90% identity. Vertebrates like Xenopus laevis (frog) and Danio rerio (bony fish) have homologs with 65% and 50% identity with human CIP2A respectively. Lower conservation of Cip2A is found throughout the animal kingdom. Nematostella vectensis (starfish) has a Cip2A homolog that has 39% identity with the human protein, but contains several deletions in the sequence, whereas Drosophila melanogaster (fly) homolog has a only 15% identity with human protein.

Implicated in

Note
  
Entity Gastric cancer
Note Several studies have shown CIP2A to be overexpressed in gastric cancer patients and cell lines (Soo Hoo et al., 2002; Li et al., 2008; Khanna et al., 2009). Furthermore, CIP2A depletion is shown to decrease proliferation, anchorage-independent growth, and expression of c-MYC protein in several gastric cancer cell lines (Khanna et al., 2009). CIP2A depletion also causes diminished clonogenic potential of tumor cells as well as induction of senescence in few gastric cancer cell lines (Li et al., 2008). Additionally, CIP2A and c-MYC immunopositivity associate in human gastric cancer specimens (Khanna et al., 2009).
Prognosis Overexpression of CIP2A is associated with reduced overall survival in gastric cancer patients with tumour ≤ 5 cm, advanced stage (pT3-T4), and p53 immunopositivity. Moreover, association between CIP2A and markers of increased cellular malignancy (high SPF) further supports the role for CIP2A in promoting cancer progression (Khanna et al., 2009).
  
  
Entity Colon carcinoma
Note CIP2A mRNA expression is shown to be overexpressed in colon cancer tissues compared to non-malignant tissue (Junttila et al., 2007).
  
  
Entity Head and neck squamous cell carcinoma (HNSCC)
Note CIP2A mRNA and protein expression is shown to be overexpressed in human HNSCC cell lines. CIP2A immunopositivity in HNSCC tumor samples is restricted to tumour cells as stroma is mostly shown to be negative. Moreover, CIP2A is shown to promote c-MYC stability and malignant growth in NSCC cells. Additionally, role of CIP2A expression in HNSCC is analyzed using a mouse model of HNSCC wherein strong CIP2A immunopositivity is shown in both hyperplastic and HNSCC tissues in comparison to DMBA treated wild type mice (Junttila et al., 2007).
  
  
Entity Breast carcinoma
Note CIP2A mRNA is not only shown to be overexpressed but also correlates with higher Scarff-Bloom-Richardson grades in samples from two independent human breast cancer patient cohorts. Furthermore, CIP2A mRNA expression positively correlated with lymph node positivity, expression of proliferations markers (Ki67) and p53 mutations in the tumor samples. Moreover, CIP2A protein expression was induced in mouse breast cancer mouse models presenting mammary gland-specific depletion of p53 and either BRCA1 or BRCA2. CIP2A depletion inhibits the expression of c-MYC, and anchorage-independent growth in breast cancer cells. Additionally, CIP2A is shown to support MDA-MB-231 xenograft growth in nude mice (Côme et al., 2009).
  
  
Entity Helicobacter pylori (H. pylori) infection
Note H. pylori infection-induced CIP2A expression in cultured cells is dependent on CagA gene expression and CagA phosphorylation. Bacterial oncoprotein, CagA upregulates CIP2A expression and this upregulation is dependent on Src and MEK/ERK pathways. H. pylori infection-induced MYC stabilization is also shown to be partially reduced on CIP2A depletion (Zhao et al., 2009).
  

To be noted

Other oncogenic properties of CIP2A: CIP2A is shown to promote Ras-elicited foci formation in mouse embryo fibroblasts and transforms immortalized human cells (HEK-TERV) (Junttila et al., 2007).

Bibliography

A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP.
Nat Biotechnol. 2006 Oct;24(10):1285-92. Epub 2006 Sep 10.
PMID 16964243
 
CIP2A is associated with human breast cancer aggressivity.
Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J.
Clin Cancer Res. 2009 Aug 15;15(16):5092-100. Epub 2009 Aug 11.
PMID 19671842
 
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M.
Mol Cell. 2008 Aug 8;31(3):438-48.
PMID 18691976
 
Mechanisms of MYC stabilization in human malignancies.
Junttila MR, Westermarck J.
Cell Cycle. 2008 Mar 1;7(5):592-6. Epub 2007 Dec 29. (REVIEW)
PMID 18256542
 
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimaki A.
J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. Epub 2009 May 26.
PMID 19470954
 
CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.
Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D.
Clin Cancer Res. 2008 Jun 15;14(12):3722-8.
PMID 18559589
 
PP2A: unveiling a reluctant tumor suppressor.
Mumby M.
Cell. 2007 Jul 13;130(1):21-4. (REVIEW)
PMID 17632053
 
Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.
Nagase T, Kikuno R, Ishikawa K, Hirosawa M, Ohara O.
DNA Res. 2000 Apr 28;7(2):143-50.
PMID 10819331
 
Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, Daniels T, Casiano CA, Heeb MJ, Chan EK, Tan EM.
Prostate. 2005 May 15;63(3):252-8.
PMID 15538718
 
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.
Soo Hoo L, Zhang JY, Chan EK.
Oncogene. 2002 Jul 25;21(32):5006-15.
PMID 12118381
 
Multiple pathways regulated by the tumor suppressor PP2A in transformation.
Westermarck J, Hahn WC.
Trends Mol Med. 2008 Apr;14(4):152-60. Epub 2008 Mar 10. (REVIEW)
PMID 18329957
 
Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways.
Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C, Jia J.
J Med Microbiol. 2010 Mar;59(Pt 3):259-65. Epub 2009 Dec 3.
PMID 19959630
 

Citation

This paper should be referenced as such :
Khanna, A ; Okkeri, J ; Westermarck, J
KIAA1524
Atlas Genet Cytogenet Oncol Haematol. 2010;14(10):976-978.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/KIAA1524ID44402ch3q13.html


Other Leukemias implicated (Data extracted from papers in the Atlas) [ 2 ]
  t(11;14)(q23;q32) KMT2A/CEP170B
t(3;11)(q13.13;q23) KMT2A/KIAA1524


External links

Nomenclature
HGNC (Hugo)KIAA1524   29302
Cards
AtlasKIAA1524ID44402ch3q13
Entrez_Gene (NCBI)KIAA1524  57650  KIAA1524
AliasesCIP2A; p90
GeneCards (Weizmann)KIAA1524
Ensembl hg19 (Hinxton)ENSG00000163507 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000163507 [Gene_View]  chr3:108549871-108589644 [Contig_View]  KIAA1524 [Vega]
ICGC DataPortalENSG00000163507
TCGA cBioPortalKIAA1524
AceView (NCBI)KIAA1524
Genatlas (Paris)KIAA1524
WikiGenes57650
SOURCE (Princeton)KIAA1524
Genetics Home Reference (NIH)KIAA1524
Genomic and cartography
GoldenPath hg38 (UCSC)KIAA1524  -     chr3:108549871-108589644 -  3q13.13   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)KIAA1524  -     3q13.13   [Description]    (hg19-Feb_2009)
EnsemblKIAA1524 - 3q13.13 [CytoView hg19]  KIAA1524 - 3q13.13 [CytoView hg38]
Mapping of homologs : NCBIKIAA1524 [Mapview hg19]  KIAA1524 [Mapview hg38]
OMIM610643   
Gene and transcription
Genbank (Entrez)AB040957 AF334474 AK022912 AK056933 AK308315
RefSeq transcript (Entrez)NM_020890
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)KIAA1524
Cluster EST : UnigeneHs.591308 [ NCBI ]
CGAP (NCI)Hs.591308
Alternative Splicing GalleryENSG00000163507
Gene ExpressionKIAA1524 [ NCBI-GEO ]   KIAA1524 [ EBI - ARRAY_EXPRESS ]   KIAA1524 [ SEEK ]   KIAA1524 [ MEM ]
Gene Expression Viewer (FireBrowse)KIAA1524 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)57650
GTEX Portal (Tissue expression)KIAA1524
Human Protein AtlasENSG00000163507-KIAA1524 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ8TCG1   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ8TCG1  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ8TCG1
Splice isoforms : SwissVarQ8TCG1
PhosPhoSitePlusQ8TCG1
Domains : Interpro (EBI)ARM-like    ARM-type_fold   
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)KIAA1524
DMDM Disease mutations57650
Blocks (Seattle)KIAA1524
SuperfamilyQ8TCG1
Human Protein Atlas [tissue]ENSG00000163507-KIAA1524 [tissue]
Peptide AtlasQ8TCG1
HPRD11151
IPIIPI00154283   IPI00789801   IPI00945075   IPI00945784   
Protein Interaction databases
DIP (DOE-UCLA)Q8TCG1
IntAct (EBI)Q8TCG1
FunCoupENSG00000163507
BioGRIDKIAA1524
STRING (EMBL)KIAA1524
ZODIACKIAA1524
Ontologies - Pathways
QuickGOQ8TCG1
Ontology : AmiGOprotein binding  cytoplasm  cytosol  plasma membrane  spermatogenesis  integral component of membrane  cadherin binding  positive regulation of neural precursor cell proliferation  
Ontology : EGO-EBIprotein binding  cytoplasm  cytosol  plasma membrane  spermatogenesis  integral component of membrane  cadherin binding  positive regulation of neural precursor cell proliferation  
NDEx NetworkKIAA1524
Atlas of Cancer Signalling NetworkKIAA1524
Wikipedia pathwaysKIAA1524
Orthology - Evolution
OrthoDB57650
GeneTree (enSembl)ENSG00000163507
Phylogenetic Trees/Animal Genes : TreeFamKIAA1524
HOVERGENQ8TCG1
HOGENOMQ8TCG1
Homologs : HomoloGeneKIAA1524
Homology/Alignments : Family Browser (UCSC)KIAA1524
Gene fusions - Rearrangements
Fusion : MitelmanCBLB/KIAA1524 [3q13.11/3q13.13]  [t(3;3)(q13;q13)]  
Fusion : COSMICKMT2A [11q23.3]  -  KIAA1524 [3q13.13]  [fusion_1833]  [fusion_1834]  
Fusion: TCGACBLB 3q13.11 KIAA1524 3q13.13 PRAD
Fusion : TICdbKMT2A [11q23.3]  -  KIAA1524 [3q13.13]
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerKIAA1524 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)KIAA1524
dbVarKIAA1524
ClinVarKIAA1524
1000_GenomesKIAA1524 
Exome Variant ServerKIAA1524
ExAC (Exome Aggregation Consortium)ENSG00000163507
GNOMAD BrowserENSG00000163507
Genetic variants : HAPMAP57650
Genomic Variants (DGV)KIAA1524 [DGVbeta]
DECIPHERKIAA1524 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisKIAA1524 
Mutations
ICGC Data PortalKIAA1524 
TCGA Data PortalKIAA1524 
Broad Tumor PortalKIAA1524
OASIS PortalKIAA1524 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICKIAA1524  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDKIAA1524
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch KIAA1524
DgiDB (Drug Gene Interaction Database)KIAA1524
DoCM (Curated mutations)KIAA1524 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)KIAA1524 (select a term)
intoGenKIAA1524
NCG5 (London)KIAA1524
Cancer3DKIAA1524(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM610643   
Orphanet
MedgenKIAA1524
Genetic Testing Registry KIAA1524
NextProtQ8TCG1 [Medical]
TSGene57650
GENETestsKIAA1524
Target ValidationKIAA1524
Huge Navigator KIAA1524 [HugePedia]
snp3D : Map Gene to Disease57650
BioCentury BCIQKIAA1524
ClinGenKIAA1524
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD57650
Chemical/Pharm GKB GenePA134887850
Clinical trialKIAA1524
Miscellaneous
canSAR (ICR)KIAA1524 (select the gene name)
Probes
Litterature
PubMed114 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineKIAA1524
EVEXKIAA1524
GoPubMedKIAA1524
iHOPKIAA1524
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 12 16:25:25 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.